Feed CRL
CR

Charles River Laboratories CRL · NYSE

$300.27 -1.95% (-$5.97)

Market cap
$14.8B
Enterprise value
$17.6B
P/E
-
Forward P/E
26.3x
PEG
-
P/S
3.7x
P/FCF
39.8x
EV/EBITDA
79.8x
ROIC
10.0%
Gross margin
32.2%
Net margin
-6.0%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
12.9x
Beta
1.40
Free float
98.0%

About the company

Charles River Laboratories International, Inc. (CRL) is an American company operating in the biotechnology and pharmaceutical research industry. The company specializes in providing preclinical and clinical services to pharmaceutical and biotechnology companies, academic institutions, and government organizations. Its services include drug testing, toxicity studies, pharmacokinetics, viral safety testing, genetic analysis, and other biological and chemical analyses. Charles River Laboratories has a broad portfolio of laboratory and clinical services that are crucial for the development of new drugs and treatment protocols. The company emphasizes quality, innovation, and ethical standards in its research and laboratory practices. It is recognized as a significant partner for the pharmaceutical and biotechnology sectors. Charles River Laboratories International, Inc. (CRL) shares are publicly traded on the stock exchange and may represent an attractive investment opportunity for investors monitoring the biotechnology and pharmaceutical industry and seeking investments in a company with a significant position in drug research and development.

Sector

Healthcare

Industry

Medical - Diagnostics & Research

CEO

Birgit Girshick

Employees

19,000

Headquarters

Wilmington

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.